28284173|t|Patient - derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour
28284173|a|Preclinical models that mimic pathological and molecular features of solitary fibrous tumour (SFT) represent an important tool to select effective regimes and novel compounds to be tested in the clinic. This study was aimed at developing two preclinical models of SFT, assessing their predictive value in the clinic and selecting potential novel effective treatments. Two dedifferentiated-SFT (D-SFT) models obtained from patients ' biopsies were grown in immunodeficient mice. The antitumour activity on these models of doxorubicin, dacarbazine (DTIC), ifosfamide (monotherapy or combination), trabectedin and eribulin was tested. Twelve SFT patients were treated with doxorubicin and DTIC. Response by RECIST, progression-free survival and overall survival were retrospectively evaluated, distinguishing malignant-SFT (M-SFT) and D-SFT. Two D-SFT patient-derived xenografts (PDXs) that represent the first available preclinical in vivo models of SFT were developed and characterised. Doxorubicin/DTIC, DTIC/ifosfamide, doxorubicin/ifosfamide combinations consistently induced better antitumour activity than the single-agents. Particularly, doxorubicin/DTIC combination caused a max tumour volume inhibition >80% in both models. Doxorubicin/DTIC combo showed activity also in the case-series. Best RECIST responses were: 6 responses (M-SFT = 2 of 7, D-SFT = 4 of 5), 1 stable disease, 5 progressions, with a 6-month median progression-free survival (M-SFT = 6, D-SFT = 10 months). The PDXs were very sensitive to trabectedin and eribulin. Doxorubicin plus DTIC combination was effective in our two D-SFT mice models and appeared to be active also in the clinic, especially in high-grade D-SFT patients. Among additional drugs tested in the PDXs, trabectedin and eribulin were highly effective, providing a rational to test these drugs in D-SFT patients.
28284173	18	41	solitary fibrous tumour	T038	UMLS:C1266119
28284173	42	52	xenografts	T103	UMLS:C0522537
28284173	81	116	doxorubicin/dacarbazine combination	T058	UMLS:C0050841
28284173	134	140	clinic	T092	UMLS:C0442592
28284173	186	197	trabectedin	T103	UMLS:C1311070
28284173	201	209	eribulin	T103	UMLS:C2350866
28284173	223	229	tumour	T038	UMLS:C0027651
28284173	230	248	Preclinical models	T170	UMLS:C1514292
28284173	299	322	solitary fibrous tumour	T038	UMLS:C1266119
28284173	324	327	SFT	T038	UMLS:C1266119
28284173	352	356	tool	T170	UMLS:C1516602
28284173	377	384	regimes	T058	UMLS:C0418956
28284173	425	431	clinic	T092	UMLS:C0442592
28284173	438	443	study	T062	UMLS:C2603343
28284173	472	490	preclinical models	T170	UMLS:C1514292
28284173	494	497	SFT	T038	UMLS:C1266119
28284173	539	545	clinic	T092	UMLS:C0442592
28284173	602	622	dedifferentiated-SFT	T038	UMLS:C2699572
28284173	624	629	D-SFT	T038	UMLS:C2699572
28284173	631	637	models	T170	UMLS:C1514292
28284173	663	671	biopsies	T058	UMLS:C0005558
28284173	686	706	immunodeficient mice	T204	UMLS:C1512658
28284173	712	731	antitumour activity	T033	UMLS:C0243095
28284173	741	747	models	T170	UMLS:C1514292
28284173	751	762	doxorubicin	T103	UMLS:C0013089
28284173	764	775	dacarbazine	T103	UMLS:C0010927
28284173	777	781	DTIC	T103	UMLS:C0010927
28284173	784	794	ifosfamide	T103	UMLS:C0020823
28284173	811	822	combination	T058	UMLS:C0013218
28284173	825	836	trabectedin	T103	UMLS:C1311070
28284173	841	849	eribulin	T103	UMLS:C2350866
28284173	869	872	SFT	T038	UMLS:C1266119
28284173	887	899	treated with	T058	UMLS:C0332293
28284173	900	911	doxorubicin	T103	UMLS:C0013089
28284173	916	920	DTIC	T103	UMLS:C0010927
28284173	934	940	RECIST	T170	UMLS:C1709926
28284173	1036	1049	malignant-SFT	T038	UMLS:C1266120
28284173	1051	1056	M-SFT	T038	UMLS:C1266120
28284173	1062	1067	D-SFT	T038	UMLS:C2699572
28284173	1073	1078	D-SFT	T038	UMLS:C2699572
28284173	1079	1105	patient-derived xenografts	T038	UMLS:C4050317
28284173	1107	1111	PDXs	T038	UMLS:C4050317
28284173	1160	1174	in vivo models	T062	UMLS:C1515657
28284173	1178	1181	SFT	T038	UMLS:C1266119
28284173	1216	1232	Doxorubicin/DTIC	T058	UMLS:C0050841
28284173	1234	1249	DTIC/ifosfamide	T058	UMLS:C0013218
28284173	1251	1286	doxorubicin/ifosfamide combinations	T058	UMLS:C0278906
28284173	1315	1334	antitumour activity	T033	UMLS:C0243095
28284173	1373	1401	doxorubicin/DTIC combination	T058	UMLS:C0050841
28284173	1415	1439	tumour volume inhibition	T038	UMLS:C1512773
28284173	1453	1459	models	T170	UMLS:C1514292
28284173	1461	1483	Doxorubicin/DTIC combo	T058	UMLS:C0050841
28284173	1512	1523	case-series	T062	UMLS:C0150093
28284173	1530	1536	RECIST	T170	UMLS:C1709926
28284173	1566	1571	M-SFT	T038	UMLS:C1266120
28284173	1582	1587	D-SFT	T038	UMLS:C2699572
28284173	1601	1615	stable disease	T033	UMLS:C0677946
28284173	1619	1631	progressions	T038	UMLS:C0242656
28284173	1682	1687	M-SFT	T038	UMLS:C1266120
28284173	1693	1698	D-SFT	T038	UMLS:C2699572
28284173	1717	1721	PDXs	T038	UMLS:C4050317
28284173	1745	1756	trabectedin	T103	UMLS:C1311070
28284173	1761	1769	eribulin	T103	UMLS:C2350866
28284173	1771	1804	Doxorubicin plus DTIC combination	T058	UMLS:C0050841
28284173	1830	1835	D-SFT	T038	UMLS:C2699572
28284173	1836	1847	mice models	T170	UMLS:C0086272
28284173	1886	1892	clinic	T092	UMLS:C0442592
28284173	1919	1924	D-SFT	T038	UMLS:C2699572
28284173	1952	1957	drugs	T103	UMLS:C0013227
28284173	1972	1976	PDXs	T038	UMLS:C4050317
28284173	1978	1989	trabectedin	T103	UMLS:C1311070
28284173	1994	2002	eribulin	T103	UMLS:C2350866
28284173	2061	2066	drugs	T103	UMLS:C0013227
28284173	2070	2075	D-SFT	T038	UMLS:C2699572